… spectrum of age studied in DAPA-HF. There was no significant imbalance in tolerability
or … the efficacy and safety of dapagliflozin according to age in a post hoc analysis of DAPA-HF. …

… treatment were eligible for DAPA-HF, which is comparing dapagliflozin 10 mg once daily
to … Consequently, DAPA-HF will test the incremental efficacy and safety of dapagliflozin in …

… safety of dapagliflozin in patients who were or were not taking sacubitril/valsartan at baseline
in the DAPA-HF (Study to Evaluate the Effect of Dapagliflozin … and safety of dapagliflozin in …

… analysis of DAPA-HF, we investigated the efficacy and safety of dapagliflozin compared
with … In this pre-specified analysis of DAPA-HF, dapagliflozin reduced the risk of the primary …

… the safety and efficacy of dapagliflozin in patients with HFrEF, according to baseline kidney
function, in the DAPA-HF trial (Dapagliflozin … We also examined the effect of dapagliflozin on …

… Our findings in DAPA-HF were qualitatively similar to those in PARADIGM-HF with the most
marked benefit in patients with the lowest baseline NT-proBNP, and there was a nominally …

… of dapagliflozin on clinical outcomes in DAPA-HF were independent of baseline frailty class.
Specifically, dapagliflozin, … reduced the risk for worsening HF or cardiovascular death to a …

… We evaluated the efficacy and safety of dapagliflozin, which lowers systolic blood pressure
(SBP),according to baseline SBP in Dapagliflozin and Prevention of Adverse Outcomes in …

… of dapagliflozin in DAPA-HF were obtained regardless of the use of background diuretic
therapy or dose of diuretic therapy. Likewise, the tolerability and safety profile of dapagliflozin …

… The overall safety profile of dapagliflozin in this analysis was comparable to that of the
placebo group, with similar frequencies of AEs occurring in both groups of patients. While renal …